Drug Approval | February 19, 2022
US FDA to review Amylyx new drug application for AMX0035
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
ArisGlobal's industry-leading regulatory software chosen by top pharmaceutical company for IDMP preparation and global readiness
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Dr. Raman has succeeded Victoria Richon
Evonik invests in start-up to improve patient recovery after open-chest surgery
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Darolutamide is developed jointly by Bayer and Orion Corporation
Subscribe To Our Newsletter & Stay Updated
